^
Association details:
Biomarker:TMB-L
Cancer:Gastric Cancer
Drug:Lynparza (olaparib) (PARP inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: D – Preclinical
Source:
Title:

2055 - Evaluation of DNA damage repair gene alterations, microsatellite instability status, and tumor mutational burden as predictive biomarkers of olaparib sensitivity in gastric cancer

Published date:
03/10/2021
Excerpt:
Three MSI-H cell lines were sensitive to olaparib, but NUGC-3 with the lowest TMB (13.8) among MSI-H cell lines was resistant.